Article

Improving Awareness of Hypopituitarism in Traumatic Brain Injury

As it's impossible to predict which traumatic brain injury patients will develop hypopituitarism, improving awareness of the condition is vital.

While affected war veterans have galvanized our search to understand traumatic brain injury (TBI), the 1.7 million individuals who incur sports-related and accidental central nervous system insults from other causes are also of concern.

Though anterior hypopituitarism is a special concern in those patients, the condition remains under-diagnosed. And while the risk of hypopituitarism is greatest in patients with severe TBI, patients with mild TBI are also at significant risk. In fact, it’s currently estimated that approximately 27.5% of those who experience TBI also suffer from hypopituitarism as a consequence of mechanical and/or ischemic injury.

In a review published in Endocrinology and Metabolism Clinics of North America, researchers from Mount Sinai Medical Center explored hypopituitarism in great detail. According to the authors, neuropsychiatric complaints and the signs and symptoms of hypopituitarism often overlap, as memory deficits, poor concentration, lack of good judgment, impaired problem solving, fatigue, anxiety, depression, and social isolation are all common to both conditions.

Nevertheless, predicting which patients will develop hypopituitarism is impossible. Therefore, improving awareness of hypopituitarism in TBI patients is vital. Though deficiencies of the growth hormones somatotropin and gonadotropin are more common than a lack of thyrotropin and corticotrophin, growth hormone deficits in general seem to bring on the most significant clinical symptoms, especially in TBI patients who haven’t achieved peak bone mass.

The authors advised clinicians to evaluate patients routinely for all hormonal deficiencies at 3 to 6 months after initial trauma, as well as document a detailed history and physical examination. In addition, the researchers recommended pituitary testing when symptoms of hypopituitarism are visible.

While many patients’ pituitary function recovers, the recovery is sometimes fleeting. At 1 year, hormone replacement should address specific pituitary deficits, though it may turn out to be a chronic need.

As clinicians become more aware of posttraumatic hypopituitarism, their collective knowledge should improve management approaches.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.